Transforming Knowledge into Insight
Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions.
Our investment perspectives are enhanced by MEDACorp's more than 30,000 healthcare professionals. Members of the MEDACorp network provide expertise on new developments in biotherapeutics, medical devices, services, and regulations on a daily basis. This extensive knowledge helps Leerink Swann provide clients with expertise earned through experience.
Award-Winning Equity Research
Leerink Swann has consistently been recognized for the quality of its healthcare research. The Leerink Swann Equity Research team was ranked among the top biotechnology and pharmaceutical stock pickers in The Wall Street Journal’s 2011 “Best on the Street” rankings. The team earned top honors in the 2011 FT/StarMine Analyst Awards: #1 Stock Picker for Pharmaceuticals, #2 Stock Picker for Biotechnology and #2 Earnings Estimator in Health Care Providers & Services. 2010 accolades include #1 Biotech Stock Picker in The Wall Street Journal's "Best on the Street" special report, and #2 Earning Estimator for Health Care Providers & Services from FT/StarMine Analyst Awards.
In the 2011 Institutional Investor poll, we were named “Rising Star of Wall Street” in Health Care Technology & Distribution. In 2008 and 2009, Leerink Swann's Medical Supplies and Devices team ranked in the Institutional Investor All-American team. Prior to that, I.I. had a “Best of Boutiques” category, where beginning in 2001, Leerink Swann ranked in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major, and Pharmaceuticals/Specialty. In 2006 and 2007, Leerink Swann added "Best Boutique in Health Care Technology & Distribution".
Universe of Coverage
Leerink Swann analysts provide regular research coverage on an extensive list of leading and emerging healthcare companies.